Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Secretome Therapeutics raises $30 million in Series A financing from RA Capital Management to advance STM-01 for Duchenne-associated cardiomyopathy.
PRIVATEMay 27, 2026•2 months ago
Amount Raised
$30 Million
Round Type
Series A
BaltimoreBiotechnologyInvestors
Ra Capital Management
Description
Secretome Therapeutics has closed a $30 million Series A financing from RA Capital Management to support the advancement of STM-01 for Duchenne muscular dystrophy-associated cardiomyopathy. This funding will help develop their neonatal cardiac progenitor cell platform further. David Lubner has joined the Board of Directors as part of the financing. The funds will facilitate pivotal Phase 2 and Phase 3 trials for STM-01.
Related People
Suggested for you
2 contactsVerified contactsMuthukumar P., Director Translational Medicine hidden hidden
Funding Insights
Based on industry dataTypical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech